Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
-
Published:2024-03
Issue:
Volume:199
Page:113530
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Brahmer Julie R., Long Georgina V., Hamid Omid, Garon Edward B., Herbst Roy S., Andre ThierryORCID, Armand PhilippeORCID, Bajorin Dean, Bellmunt JoaquimORCID, Burtness Barbara, Choueiri Toni K., Cohen Ezra E.W., Diaz Luis A., Shitara KoheiORCID, Kulkarni Girish, McDermott David, Shah Manish, Tabernero JosepORCID, Vogel ArndtORCID, Zinzani Pier Luigi, Jafari Niusha, Bird Steven, Snyder EllenORCID, Gause Christine, Bracco Oswaldo L., Pietanza M. Catherine, Gruber ToddORCID, Ribas AntoniORCID
Subject
Cancer Research,Oncology
Reference7 articles.
1. KEYTRUDA® (pembrolizumab) injection, for intravenous use. 04/2023. Merck & Co., Inc., Rahway, NJ, USA. 2. KEYTRUDA 25 mg/mL concentrate for solution for infusio (summary of product characteristics). 2023, Merck Sharp & Dohme B.V., Haarlem, Netherlands. 3. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy;Ghisoni;Eur J Cancer,2021 4. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis;Wang;Front Pharm,2017 5. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma;Robert;Eur J Cancer,2021
|
|